Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatous skin cancers. Cemiplimab is now a standard of care for patients with locally advanced, unresectable or metastatic cSCC, and is particularly effective in patients with cancer driven by UV-induced DNA damage. However, oncologists and researchers are always looking for new and better ways to use established treatments. At ESMO 2023 two papers took this approach; one examined moving immunotherapy to the neoadjuvant space, while another added a venerable EGFR inhibitor to treatment of advanced cSCC. However, the undoubted star of this show is the long-term results of tebentafusp, the first efficacious treatment of a subtype of the notorious uveal melanoma. ESMO 2023 truly had something for everyone, and the melanoma and skin cancer areas were no exception.
Studies discussed in today's episode (subscription may be required)
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
","author_name":"Michael Fernando and Josh Hurwitz"}